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Abstract
Expression of prostasin in the PC-3 human prostate carcinoma cells inhibited in vitro invasion, but the molecular mechanisms are unknown.
Wild-type human prostasin or a serine active-site mutant prostasin was expressed in the PC-3 cells. Molecular changes were measured at the
mRNA and the protein levels. Cell signaling changes were evaluated by measuring phosphorylation of the extracellular signal-regulated kinases
(Erk1/2) following epidermal growth factor (EGF) treatment of the cells. Protein expression of the EGF receptor (EGFR) was differentially down-
regulated by the wild-type and the active-site mutant prostasin. The mRNA expression of EGFR and the transcription repressor SLUG was
reduced in cells expressing wild-type prostasin but not the active-site mutant. Phosphorylation of Erk1/2 in response to EGF was greatly reduced
by the wild-type prostasin but not by the active-site mutant. The mRNA expression of the urokinase-type plasminogen activator (uPA), the uPA
receptor (uPAR), cyclooxygenase-2 (COX-2), and the inducible nitric oxide synthase (iNOS) was decreased by the wild-type and the active-site
mutant prostasin. The mRNA or protein expression of granulocyte-macrophage colony-stimulating factor (GM-CSF), matriptase, and E-cadherin
was greatly increased by the active-site mutant prostasin. In conclusion, prostasin expression elicits both protease-dependent and independent
molecular changes in the PC-3 cells.
© 2007 Elsevier B.V. All rights reserved.
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1. Introduction
Since its discovery more than a decade ago, prostasin, a
glycosylphosphatidylinositol (GPI)-anchored extracellular ser-
ine protease has been shown to play important roles in epithelial
physiology. These functional roles include suppression of inva-
sion [1,2], regulation of gene expression during inflammation
[3], and activation of the epithelial sodium channel (ENaC) [4].
Activation of ENaC by prostasin is mechanistically the best-
defined function for prostasin, with very recent data consistent
with a proteolytic cleavage of the gamma subunit of ENaC by
prostasin [4]. The other in vitro and in vivo phenotypic changes
induced by prostasin remain mechanistically undefined. We
undertook the current study to probe into the potential
molecular mechanisms by which prostasin impacts the cell’s
behavior. We used the PC-3 human prostate carcinoma cell line,
which has a compromised prostasin expression due partly to
promoter DNA hypermethylation [5]. Upon prostasin re-
expression the PC-3 cells displayed reduced in vitro invasion
through a Matrigel barrier [1]. We focused on the extracellular
molecular players in tumor invasion previously established for
this cell line, because prostasin is an active serine protease
anchored to the outside of the plasma membrane [6].
The epidermal growth factor receptor (EGFR) was the first
member of the erbB family of receptor tyrosine kinases to be
discovered and the first cell surface receptor to be shown with a
role in cancer biology [7]. EGFR overexpression is implicated
for a causative role in ten different types of solid tumor [8].
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Cellular signals initiated by activation of this receptor tyrosine
kinase confer cancer cells with advantages in angiogenesis,
growth, and motility [9]. The PC-3 cell line is a high expresser
of EGFR [10], which is a major mediator of prostate cancer cell
motility and invasiveness [11]. The urokinase-type plasminogen
activator (uPA), a serine protease, through interactions with its
membrane receptor, the GPI-anchored uPAR, also promotes
prostate cancer invasiveness [12]. The invasion promoting
effect of the uPA-uPAR signaling route in the PC-3 cell line is
modulated by an EGFR tyrosine kinase inhibitor (AG1478)
[13], reducing uPA production [14]. E-Cadherin, a cell–cell
adhesion molecule and a tumor suppressor, is down-regulated in
the PC-3 cell line [15], resulting in increased invasive behavior
[16]. The PC-3 cell line expresses the granulocyte-macrophage
colony-stimulating factor (GM-CSF), which, acts in an
autocrine loop to stimulate the tumor cells [17]. GM-CSF
release is also regulated by the EGFR signaling pathway [18].
These target genes and proteins were investigated in PC-3 cells
expressing either a wild-type human prostasin or a serine active-
site mutant.
The prostasin serine protease can be activated by the type-II
transmembrane extracellular serine protease matriptase in vitro
and in vivo [19]. Inhibition of matriptase expression in the PC-3
cells resulted in suppression of invasion [20]. Prostasin
expression in the prostate is regulated at the transcription
level partly by promoter DNA methylation [5], and partly by
transcription factors such as the sterol-regulatory element-
binding proteins (SREBP’s), the SNAIL and the SLUG [21].
SLUG is a well-known E-cadherin expression repressor and an
inducer of epithelial–mesenchymal transition (EMT) [22], and
is up-regulated by EGF [21]. The inflammation-associated
expression of the inducible nitric oxide synthase (iNOS), but not
of the cyclooxygenase-2 (COX-2) was attenuated in the mouse
bladder by prostasin [3]. In PC-3 cells expressing the wild-type
or the mutant prostasin, we also examined the expression states
of these regulators of prostasin expression, and genes that are
regulated by prostasin.
2. Materials and methods
2.1. Materials
The human prostate carcinoma cell line PC-3 (Passage 18) was obtained
from the American Type Culture Collection (ATCC, Manassas, VA), and
cultured in conditions previously described [1]. A polyclonal antibody against
human prostasin was described previously [6]. Polyclonal antibodies to EGFR
(sc-03), Erk1/2 (sc-94), and a monoclonal antibody to glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (sc-32233) were purchased from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA). A monoclonal antibody to E-
cadherin (C20820) was purchased from BD Biosciences (San Jose, CA). A
monoclonal antibody to human matriptase (M32) was described previously [23].
A polyclonal antibody against phospho-Erk1/2 (V803A) was purchased from
Promega (Madison, WI). A recombinant human EGF was purchased from
Invitrogen (Carlsbad, CA).
2.2. Cell culture and transfection
PC-3 cells were transfected with episomal expression plasmids carrying a
wild-type human prostasin cDNA, or an active-site mutant prostasin cDNA,
using methods previously described [1]. Construction of the episomal
expression plasmids and the mutant prostasin cDNA was described previously
[1,3]. Transfectants harboring the control plasmid, expressing the wild-type
prostasin, or expressing the mutant prostasin were plated in 60-mm dishes and
cultured to confluence for harvest of the culture medium, and the cells.
2.3. RNA isolation, and reverse transcription-real-time polymerase
chain reactions (RT-rtPCR)
Confluent monolayers were lysed with the Trizol reagent (Invitrogen) for
total cellular RNA isolation per supplier’s protocol. Reverse transcription was
carried out for each sample using the iScript cDNA Synthesis Kit (Bio-Rad,
Hercules, CA) per supplier’s protocol. Real-time polymerase chain reaction was
carried out for each sample using the iQ SYBR Green Supermix (Bio-Rad) per
supplier’s protocol. PCR programs and methods of quantification were
described previously [3]. The message number of the GAPDH was used as
the reference for calculating specific gene messages. PCR primers for GAPDH
and SLUG were described previously [3,21]. PCR primers for the following
human gene transcripts are listed in the order of forward and reverse:
COX-2 5′-CCT CCT GTG CCT GAT GAT TG-3′
5′-ACT GAT GCG TGA AGT GCT G-3′
E-Cadherin 5′-AGA ATG ACA ACA AGC CCG AAT-3′
5′-CGG CAT TGT AGG TGT TCA CA-3′
EGFR 5′-CTG ACC AAA ATC ATC TGT GCC C-3′
5′-CGT GGC TTC GTC TCG GAATT-3′
GM-CSF 5′-AGC CAC TAC AAG CAG CAC-3′
5′-ACA AGC AGA AAG TCC TTC AG-3′
iNOS 5′-ATC TCT GGT CAA GCT GGATGC-3′
5′-GCC TTA TGG TGA AGT GTG TCT TG-3′
Matriptase 5′-GTC CTG CTC ATC ACA CTG-3′
5′-GTC AAT GTT GGG TGG GTA G-3′
uPA 5’-GAC ATT GCC TTG CTG AAG-3′
5′-CGG ATA GAG ATA GTC GGT AG -3′
uPAR 5′-CAC TCA GAG AAG ACC AAC AG-3′
5′-GCA CAA GTC TAA CCC ACA C-3′
2.4. Enzyme-linked immunosorbant assay (ELISA)
A Quantikine™ human GM-CSF immunoassay kit (R&D Systems,
Minneapolis, MN) was used for determining the quantities of secreted GM-
CSF in the medium collected from the PC-3 transfectant cultures. The medium
was collected at 48 h after a fresh medium change over sub-confluent cultures.
The assay was performed per supplier’s protocol. Quantities of GM-CSF were
expressed as pg/ml after normalizing with the cell number in the culture dishes.
2.5. Western blot analysis
Total cell lysate harvested from each cell type at equal amounts for all cell
types, was subjected to western blot analysis with appropriate antibodies as
described previously [6]. Each membrane was re-blotted with a GAPDH
antibody as a control for protein loading. For each sample, 40 μg of protein were
loaded, except for the phospho-Erk1/2 blot for which 20 μg of protein per
sample were loaded. The antibodies were used at the following dilutions:
prostasin at 1:5,000, GAPDH (sc-32233) at 1:5,000, EGFR (sc-03) at 1:4,000,
phospho-Erk1/2 (V803A) and Erk1/2 (sc-94) at 1:5,000, matriptase (M32) at
1:2,500, and E-cadherin (C20820) at 1:2,000. Appropriate secondary antibodies
conjugated to horse-radish peroxidase (HRP) were used at 1:10,000, and signals
were developed by enhanced chemilluminescence (ECL). Specific target protein
signals were digitally quantified and normalized against the quantity of the
GAPDH signal.
2.6. EGF treatment of cells and analysis of EGF signaling pathway
activation
Confluent PC-3 transfectants were placed under serum-free medium for
overnight, and EGF treatment of the cultures was performed for 15 min at
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50 ng/ml concentration of EGF, diluted in serum-free medium. The cells were
then immediately applied to western blot analysis for total Erk1/2 and
phospho-Erk1/2. Relative changes of the phosphorylation state of Erk1/2 were
determined following digital signal quantification and normalization against
total Erk1/2 levels.
2.7. Statistical analysis
Expression level evaluation using the western blot densitometry data, or the
quantitative real-time PCR data was performed by comparing the “means”,
wherein the data graphed or listed in the table represent the Means±Standard
Error (SE). The Student t-test (one-tailed, equal variance) was employed for
assessing statistical difference (defined as when pb0.05) between data groups.
3. Results
3.1. EGFR signaling pathway is down-regulated by prostasin
The wild-type and the serine active-site mutant prostasin
proteins were expressed in the PC-3 cells at equal quantities, as
shown by the results of a western blot analysis (Fig. 1).
At the protein level, EGFR expression was down-regulated
by the wild-type prostasin and the serine active-site mutant
prostasin expressed in the PC-3 cells, by 66% and 48%,
respectively, when compared to cells carrying the control
plasmid (Fig. 2A). The wild-type prostasin expressed in the
PC-3 cells also down-regulated EGFR mRNA expression by
34%when compared to cells carrying the control plasmid, while
the mutant prostasin did not affect EGFR mRNA expression
(Fig. 2B, and Table 1). At the cellular function level, only the
wild-type prostasin was able to inhibit EGF-EGFR signaling,
with a 61% reduction of Erk1/2 phosphorylation following EGF
stimulation, when compared to cells carrying the control plasmid
(Fig. 2C). The mutant prostasin did not have an effect on Erk1/2
phosphorylation after the EGF stimulation.
3.2. Expression of SLUG, uPA, and COX-2 is down-regulated
differentially by the wild-type and the mutant prostasin
At the mRNA level, expression of SLUG was down-
regulated by the wild-type prostasin expressed in the PC-3 cells,
by 71%, when compared to cells carrying the control plasmid,
while the mutant prostasin had no effect on SLUG mRNA
expression (Fig. 3A, and Table 1).
For uPA or COX-2, however, both the wild-type and the
mutant prostasin were able to down-regulate the mRNA
expression, but with the wild-type prostasin displaying a more
robust phenotype (i.e., statistically different from the mutant
phenotype). The wild-type prostasin reduced uPA or COX-2
mRNA expression by 72.5% or 79%, respectively; while the
mutant prostasin was only able to reduce uPA or COX-2 mRNA
expression by 31% or 31%, respectively (Fig. 3B and C, and
Table 1).
3.3. Expression of uPAR and iNOS is down-regulated by both
the wild-type and the mutant prostasin
At the mRNA level, expression of uPAR was down-
regulated equally well, by 27%, by the wild-type prostasin, or
the mutant prostasin expressed in the PC-3 cells, when
compared to cells carrying the control plasmid (Fig. 4A, and
Table 1).
For the iNOS mRNA, wild-type prostasin down-regulated its
expression in the PC-3 cells by 70%, while the mutant prostasin
down-regulated the iNOS mRNA by 68%, when compared to
cells carrying the control plasmid (Fig. 4B, and Table 1). There
is no statistical difference in iNOS mRNA expression levels of
the cells expressing the wild-type prostasin and those expres-
sing the mutant.
3.4. Expression of GM-CSF, matriptase, and E-cadherin is
up-regulated by the serine active-site mutant prostasin
At the mRNA level, GM-CSF expression was up-regulated
by the mutant prostasin expressed in the PC-3 cells, to 2.66
fold, when compared to cells carrying the control plasmid (Fig.
5A, and Table 1). On the other hand, wild-type prostasin
expressed in the PC-3 cells produced a down-regulation effect
on GM-CSF mRNA expression, reducing it to 79% of that in
the control cells. The mRNA level changes of GM-CSF
expression are reflected by the quantitative changes of the
secreted GM-CSF in the culture medium (Fig. 5B). The mutant
prostasin increased the amount of secreted GM-CSF to 3.2 fold
of that of the control cells, while the wild-type prostasin
reduced the amount to 69%.
For the matriptase mRNA, only the mutant prostasin
expressed in the PC-3 cells had an effect on its expression,
increasing it to 16.8 fold of that in the control cells (Fig. 5C, and
Table 1). At the protein level, only in the mutant prostasin-
expressing cells was the matriptase band detected in the western
blot analysis (Fig. 5D).
For the E-cadherin mRNA, both the wild-type and the
mutant prostasin expressed in the PC-3 cells had an inducing
effect on its expression, increasing it to 1.9 fold and 16.6 fold,
respectively, of that in the control cells (Fig. 5E, and Table 1).
At the protein level, the changes corresponded to the mRNA
changes, with the wild-type prostasin increasing the cellular E-
cadherin protein to 2.1 fold, and the mutant prostasin, 7 fold,
Fig. 1. Expression of the wild-type and a serine active-site mutant prostasin in
PC-3. A representative western blot analysis of total lysate from PC-3 cells
transfected with a vector control plasmid (PC-3/Vec), a wild-type human
prostasin cDNA plasmid (PC-3/Pro), and a serine active-site mutant prostasin
cDNA plasmid (PC-3/ProM).
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over the level of E-cadherin protein in the vector control cells
(Fig. 5F).
4. Discussion
In this report, we present our initial findings in the efforts of
defining the molecular mechanisms by which prostasin serine
protease, as an extracellular enzyme, impacts epithelial cell
behavior. We have previously determined that in human
prostate and breast cancer cells that lost prostasin expression,
an anti-invasion phenotype was associated with the re-
expression of prostasin, while cell proliferation in vitro or in
vivo was not affected [1,2]. In this report, we focused our
attention on the molecules that play a role in the invasive
behavior of a model cell line, the human prostate cancer cell line
PC-3.
Fig. 2. Regulation of EGFR expression and EGF-EGFR signaling in PC-3 by the wild-type and the mutant prostasin. (A) Western blot analysis of EGFR in PC-3
transfected with a vector control plasmid (PC-3/Vec), a wild-type human prostasin cDNA plasmid (PC-3/Pro), and a serine active-site mutant prostasin cDNA plasmid
(PC-3/ProM). Relative EGFR expression levels between PC-3/Vec, PC-3/Pro, and PC-3/ProM were determined following densitometric measurement of the specific
protein bands and normalization against the GAPDH signals, as shown in the bar graph to the right. Calculations were based on data from three independent
experiments. The single-asterisk indicates a statistical difference between the PC-3/Vec and the PC-3/Pro, or between the PC-3/Vec and the PC-3/ProM data groups
(pb0.05). The double-asterisk indicates a statistical difference between the PC-3/Pro and the PC-3/ProM data groups (pb0.05). (B) Real-time PCR analysis of reverse-
transcribed cellular RNA for expression of EGFR. Experimental groups are as indicated under each data column, representing relative levels of expression normalized
to the mRNA level of GAPDH. The single-asterisk indicates a statistical difference between the PC-3/Vec and the PC-3/Pro data groups (pb0.05). Calculations were
based on data from four independent experiments. (C) Western blot analysis of Erk1/2 phosphorylation in response to EGF stimulation. Relative Erk1/2
phosphorylation levels between PC-3/Vec, PC-3/Pro, and PC-3/ProM were determined following densitometric measurement of the phospho-Erk2 bands and
normalization against the total Erk2 bands, as shown in the bar graph to the right. Calculations were based on data from three independent experiments. The single-
asterisk indicates a statistical difference between the PC-3/Vec and the PC-3/Pro data groups (pb0.05).
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The PC-3 cells were shown to display active prostasin
protease on the membrane upon re-expression [6]. This cell line
also presents the prostasin-activating enzyme, matriptase [20],
and in our hands we confirmed an mRNA-level matriptase
expression (Fig. 5C, and Table 1). We then used our sublines
expressing the wild-type or the active-site mutant prostasin to
investigate the molecular mechanisms that are dependent or
independent of prostasin’s protease function.
The first target molecules that we examined were the EGFR
and those regulated by the EGFR during tumor invasion. The
EGFR was identified as a major player in prostate cancer
invasion, in vivo, and in vitro in the model cell line PC-3. The
EGF-EGFR signaling initiates on the outside of the cell, where
prostasin serine protease is located. We first evaluated the
potential of prostasin to regulate EGFR protein expression in
the PC-3 cells following re-expression. wild-type prostasin
produced a 66% reduction of EGFR protein expression when
compared to the control cells (Fig. 2A). At the mRNA level, a
34% reduction of EGFR expression was also observed in the
cells expressing the wild-type prostasin (Fig. 2B, and Table 1).
Moreover, the wild-type prostasin but not the serine active-site
mutant down-regulated EGF-EGFR signaling, as EGF-stimu-
lated Erk1/2 phosphorylation was reduced by 61% (Fig. 2C). It
had been shown previously that EGF-EGFR signaling could
regulate EGFR mRNA expression in prostate cancer cell lines,
including the PC-3 [24]. Our observation on EGFR expression
regulation by prostasin is consistent with a model of EGFR
protein down-regulation followed by EGFR mRNA down-
regulation. In the PC-3 cells, activation of the EGF-EGFR
signaling pathway does not stimulate cell proliferation [25]. The
Table 1









PC-3/Vec EGFR 7.06±0.27×10−3 1.0
PC-3/Pro EGFR 4.65±0.16×10−3 0.66*
PC-3/ProM EGFR 5.84±0.65×10−3 nsd
PC-3/Vec SLUG 1.42±0.08×10−2 1.0
PC-3/Pro SLUG 0.41±0.02×10−2 0.29*
PC-3/ProM SLUG 1.18±0.10×10−2 nsd
PC-3/Vec uPA 2.29±0.10×10−1 1.0
PC-3/Pro uPA 0.63±0.04×10−1 0.275*ϕ
PC-3/ProM uPA 1.59±0.03×10−1 0.69*
PC-3/Vec uPAR 2.87±0.10×10−2 1.0
PC-3/Pro uPAR 2.09±0.12×10−2 0.73*
PC-3/ProM uPAR 2.10±0.05×10−2 0.73*
PC-3/Vec COX-2 9.69±0.51×10−4 1.0
PC-3/Pro COX-2 1.99±0.23×10−4 0.21*ϕ
PC-3/ProM COX-2 6.73±0.60×10−4 0.69*
PC-3/Vec iNOS 5.55±0.97×10−5 1.0
PC-3/Pro iNOS 1.65±0.22×10−5 0.30*
PC-3/ProM iNOS 1.79±0.23×10−5 0.32*
PC-3/Vec GM-CSF 3.60±0.21×10−4 1.0
PC-3/Pro GM-CSF 2.84±0.12×10−4 0.79*ϕ
PC-3/ProM GM-CSF 9.56±0.32×10−4 2.66*
PC-3/Vec Matriptase 3.68±0.48×10−4 1.0
PC-3/Pro Matriptase 3.53±0.45×10−4 nsd
PC-3/ProM Matriptase 6.195±0.51×10−3 16.8*
PC-3/Vec E-Cadherin 9.23±1.13×10−4 1.0
PC-3/Pro E-Cadherin 1.79±0.10×10−3 1.9*ϕ
PC-3/ProM E-Cadherin 1.53±0.18×10−2 16.6*
Real-time PCR analysis of reverse-transcribed cellular RNA from PC-3 cells
transfected with a control plasmid (PC-3/Vec), a wild-type human prostasin.
cDNA plasmid (PC-3/Pro), and a serine active-site mutant prostasin cDNA
plasmid (PC-3/ProM). Experiments were performed at least four times.
Calculations in the table were based on data from four representative
experiments.
* Indicates a statistical difference (pb0.05) between the PC-3/Vec and the PC-3/
Pro, or between the PC-3/Vec and the PC-3/ProM data groups.
ϕ Indicates a statistical difference (pb0.05) between the PC-3/Pro and the PC-3/
ProM data groups.
nsd: No statistical difference, between the data group indicated and PC-3/Vec.
Fig. 3. Real-time PCR analysis of reverse-transcribed cellular RNA for
expression of SLUG (A), uPA (B), and COX-2 (C). Experimental groups are
as indicated under each data column, representing relative levels of expression
normalized to the mRNA level of GAPDH. The single-asterisk indicates a
statistical difference between the PC-3/Vec and the PC-3/Pro, or between the
PC-3/Vec and the PC-3/ProM data groups (pb0.05). The double-asterisk
indicates a statistical difference between the PC-3/Pro and the PC-3/ProM data
groups (pb0.05). Calculations were based on data from four independent
experiments.
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Erk1/2 phosphorylation down-regulation by the wild-type
prostasin is consistent with its anti-invasion but non-anti-
proliferation phenotype [1]. We have demonstrated previously
that EGF stimulation up-regulates SLUG expression while
SLUG is a repressor of prostasin expression [21]. Here we
showed that the wild-type prostasin is capable of down-
regulating SLUG expression (Fig. 3A and Table 1). The EGF-
EGFR signaling pathway down-regulation by prostasin may
very well be the underlying mechanism for the SLUG down-
regulation. Prostasin is essential for maintaining tight junction
protein expression and tight junction formation [26], while
SLUG is a robust repressor of E-cadherin expression [22]. In
this regard, the reciprocal expression regulation between
prostasin and SLUG mediated by EGF-EGFR may play a
functional role in epithelial differentiation.
The serine active-site mutant prostasin also produced a
protein-level EGFR down-regulation, at 48% (Fig. 2A), but not
as great as the down-regulation observed with the wild-type
prostasin. The mutant prostasin, however, did not have an effect
on the EGFR mRNA expression (Fig. 2B, and Table 1) or EGF-
stimulated Erk1/2 phosphorylation (Fig. 2C). A possible
explanation is that the extent of the mutant prostasin-associated
EGFR protein down-regulation was not at a threshold point to
affect the effective number of surface receptor presentation to
impact receptor binding-activated signaling or EGFR mRNA
expression.
The uPA mRNA was down-regulated by the wild-type
prostasin in the PC-3 cells (Fig. 3B, and Table 1), a result that is
consistent with the invasion-suppressing role of prostasin [1].
This result is also consistent with an EGF-EGFR-stimulated
uPA expression [14] being down-regulated by the wild-type
prostasin. Both the wild-type and the mutant prostasin were
shown to down-regulate the uPAR mRNA expression (Fig. 4A,
and Table 1), but the mechanism and the impact of this
regulation are unclear. It is also difficult to speculate, at present,
on the mechanism or impact of the uPA expression down-
regulation by the mutant prostasin (Fig. 3B, and Table 1).
We have observed several molecular changes associated
with the expression of the active-site mutant prostasin in PC-3
cells. It must be emphasized that these molecular changes are
experimental artifacts because this form of the prostasin
protein does not exist in nature. Its value to our investigation is
to help identify the proteins that directly interact with
prostasin, allowing us to establish whether they are potential
substrates of the prostasin serine protease. Our results on the
EGFR protein and mRNA expression following prostasin and
mutant prostasin re-expression in the PC-3 cells are consistent
with a proteolytic processing role for prostasin on a new
candidate substrate, the EGFR. On the other hand, we cannot
rule out at present that the EGFR expression changes resulted
first from a transcriptional regulation. We did not observe an
apparent proteolytically processed EGFR band in our western
blots. But the potentially cleaved EGFR could be rapidly
internalized and degraded. Further research is required to
ascertain the timing and sequence of EGFR expression
regulation by prostasin.
Bruns et al. [4] recently reported that the proteolytic
activation of the gamma subunit of the ENaC is carried out
by prostasin, but they also noted that the serine active-site
mutant prostasin produced a similar proteolytic effect. A
potential mechanism was offered to explain the apparent
proteolytic effect of the serine active-site mutant prostasin on
ENaCgamma, that it could have retained a residual serine
protease activity. An alternative explanation was that the
abundance of over-expressed prostasin, wild-type or mutant,
could have exhausted the supply of serine protease inhibitors,
allowing other proteases to take action. We have observed in the
PC-3 cells, however, a dramatic inducing effect by the mutant
prostasin, on the activating serine protease, matriptase.
Matriptase and prostasin share a great deal in substrate
preference, for example, cleaving the Gln–Ala–Arg-X type of
substrates [5,27]. It is plausible that in the experiments
performed to confirm prostasin cleavage of ENaCgamma, the
mutant prostasin transfected into the cells also induced
matriptase expression to cleave ENaCgamma.
The biological relevance of mutant prostasin-induced gene
expression requires careful consideration as such is the case
with the E-cadherin expression. The wild-type prostasin
produced a moderate induction effect on E-cadherin expression,
a result that is also consistent with prostasin’s anti-invasion role.
A robust induction of E-cadherin expression at the mRNA level
and the protein level, however, was observed in cells expressing
the mutant prostasin. This induction appears to correlate with
Fig. 4. Real-time PCR analysis of reverse-transcribed cellular RNA for
expression of uPAR (A) and iNOS (B). Experimental groups are as indicated
under each data column, representing relative levels of expression normalized to
the mRNA level of GAPDH. The single-asterisk indicates a statistical difference
between the PC-3/Vec and the PC-3/Pro, or between the PC-3/Vec and the PC-3/
ProM data groups (pb0.05). Calculations were based on data from four
independent experiments.
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that of the matriptase expression, suggesting that matriptase and
prostasin may have an overlapping point in the mechanisms and
pathways by which they modulate cell signaling.
We also investigated two inflammation-induced genes for
potential regulation by prostasin in the PC-3 cells, namely
COX-2 and iNOS. Induction of bladder iNOS mRNA by
inflammation was attenuated by prostasin, while induction of
bladder COX-2 mRNA was not [3]. Prostasin did not regulate
inflammation-induced COX-2 expression in the bladder
because it is not co-expressed in the COX-2 producing cells
[3]. We tested the expression of these two genes in response to
prostasin re-expression in the PC-3 cells, and found that both
the wild-type prostasin and the mutant prostasin produced a
down-regulation on both COX-2 and iNOS (Figs. 3C and 4B,
and Table 1). For COX-2 the down-regulation by the mutant
prostasin was not as great as that by the wild-type prostasin, but
for iNOS, the two versions of prostasin were equally effective.
We could reason from these results that prostasin is also capable
of regulating COX-2 expression, in cells where it is co-
expressed with COX-2. We did not observe a down-regulation
of iNOS expression by the mutant prostasin in the bladder
inflammation model [3], but an effect was seen in the PC-3 cells
in the present study. It is also possible that an induction of other
membrane-type extracellular proteases, such as matriptase, was
Fig. 5. The serine active-site mutant prostasin induces the expression of GM-CSF (A and B), Matriptase (C and D), and E-Cadherin (E and F). Experimental groups are
as indicated under each data column, or over each sample, representing relative levels of expression normalized to the mRNA/protein level of GAPDH, whichever
appropriate. The single-asterisk indicates a statistical difference between the PC-3/Vec and the PC-3/Pro, or between the PC-3/Vec and the PC-3/ProM data groups
(pb0.05). The double-asterisk indicates a statistical difference between the PC-3/Pro and the PC-3/ProM data groups (pb0.05). Calculations of the mRNA expression
levels were based on data from four independent experiments. Calculations of the protein expression levels were based on data from three independent experiments.
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responsible for the COX-2 or iNOS expression down-regulation
in PC-3 cells expressing the mutant prostasin.
In conclusion, prostasin re-expression in the PC-3 human
prostate carcinoma cells induced serine protease-dependent and
apparently serine protease-independent molecular changes. The
protease-dependent changes are considered biologically rele-
vant, while it will require further research investigation to
determine the biological relevance of the protease-independent
changes.
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